Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
@driftking
The UK house builders were strong armed by the snake Gove to remediate the cladding c**k ups, when it was the fault of British standards, regulations etc, so the bill should have been picked up by the taxpayer.
however (rant over!) this would have dented the price for the last year, until the works are complete, it is only estimated how much this will hamstring the builders. I expect there are other factors, as stevebt points out, and the economic cycle does not favour house builders ATM.
OIL wise, Shell and BP were amongst the first shares I bought in my SIPP many years ago. "Never sell Shell" was a stoke market adage, well I did when they slapped the windfall tax on 'em, sold NG, and SSE as well 'coz these Tories are bad, but Labour may well, if not re-nationalise, windfall tax anything that shows a profit and doesn't move!
You are right, this has been already announced. I worded badly sorry, I was looking at, provision in 2020 financial year, was it in the teens millions? Then new rules, another 30 odd, then tweaks and 30 odd this year. Suppose I should be grateful it has not been increased!
Like the rest of the builders, it is a trawl to find out what the cost is, if it will increase, and most importantly, how many buildings are done! I.E. when this scam can be put behind the builders, and Labour start taxing them for windfall profits!
So another 30 odd million, and no further divies. i didn't expect the divies, but am seething at Gove shifting the remedial costs onto builders when they complied with the legislation at the time. Different story with the jabs!
I am especially sore, because I own other builders too, who have also taken a kicking.
However, when I worked in the industry, WJ seemed a well run outfit, so I'll be adding when this inevitably drops into the forties, as the divi yield should correct to less than 3%?
Thanks notrex, a rather depressing, but ultimately true read. the politics and hence policies of envy always turn out bad after time.
The world is unfair, but to try and put that right, and the "winners" vote with their feet!
Thanks for the info belgrano.
I suppose they always catch up in the end then? As I love the numbers, but hate a share where the company is dependant on one revenue stream that is unreliable, I think I will have to sell, maybe after the next ex div (or the one after that!)
It is not just that the product in worst case scenario can't be sold, it's that money is effectively given away until the "promise" of payment is forthcoming. For me, this makes a bit of a mockery of the balance sheet.
Manan - Is that a rhetorical question?
If not, the answer you are looking for is KRG being tardy with months of invoices.
I should know, because I read todays results release in detail, a shame I did not do my research before buying the stock last year!
Blinded by the dividends, but of course, the KRG have only been messing about since. I expect GKP have to be careful how they treat them, but I would like to see capex throttled until KRG play ball. Slow walk things for a while.
@Codejunkie I agree with everything you have said in your 11:14 post. I too am here until take over or multi bag territory. It would be better if the SP didn't swing about so wildly of course, and that seems partly caused because of lack of news, then very good, then lack etc..
Also, it seems the nature of AIM, and the attraction of day traders to shares like AVCT.
As you say, we need patience, it always seems the big inflection points are 6 to 12 months away!
I keep one eye on this board, and am disappointed to see the SP slide. There is a lot of discussion about the lack of comms being a factor, of course it is, but is it Al's job to constantly reassure PIs?
When the SP is high, he is "Sir Al", when low, well gets called all sorts!
CodeJunkie put his or her finger on it, with a complaint as it happens,
"its crap, but they seem to be stuck in being scientists and not making the move to smooching investors."
I would prefer them to stick to the science TBH, that is where the money is, not smooching PIs with promises. Having said that, a RNS if DE5 has started would be expected, so I guess it hasn't. Micro reasons why, do not need to be comm'ed, let them get on with the day job.
That struck me too. On page 88, conclusions, it is stated, "Doxorubicin concentrations are higher in tumour biopsies compared to plasma at 24 hrs timepoint" so logic would say the cancer is also in the liver of these patients. I note, the one biopsy was lung.
I also note, while everyone is getting a hard on (or flutters!) about the table on slide 84, and rightly so, I wonder how many realise the dox only tissue to plasma ratio is about 50. Because of the "massive nucleotide intercalation" don't you know!
My Friday night reading of the paper seemed, from my amateur understanding, that the levels in the plasma were about half with AVA6K compared to straight dox. So yes, it works, and it would seem works well, 2 to 3 times amount of treatment with much reduced side effects is forecast.
Last week I tried to sell some of my holding to take some profit, luckily my broker could not get a quote. I think that luck has saved me thousands, as I have moved from hopeful but nervous, to a signed up member of team ramper!
Well done all at AVCT, the future is looking bright.
Just come back here, and a few replies directed to me.
Hanoihank, I admit to being a layman, but do think I realise the principal of the tech. As you say, the less cleaved where it is not wanted, the more available to the TME, but as Touk pointed out, the fact doesn't conflict with what I was trying to say.
Oamot, Vertizea, gmcc et all, - I had not seen the 18x statement, so thanks for the flag and link. I note this compares to heart amounts v TME. Having read the PDF linked by Vertizea, It looks from the graph shown that at 6x normal MTD, there is 18x dox in the TME, and slightly less in the heart. I do note however that there is much more FAPa in mouse plasma.
So it still comes down to two facts to be a world beater. One that the dox (in this case) does not cleave in harmful amounts in the body at large, even at higher than standard doses. That box has been ticked.
Two, that the higher amounts available ( Ok HH?) are cleaved at useful amounts in the TME. Yes you cry, "significant" "therapeutic levels" well those words are very encouraging, some hard data could nail it on, even if I would need them interpreting for me!
Lastly, if ava6k was so good at not cleaving in the heart, lets say for example 0.01% of the dox given, and 18x were cleaved in the TME, then at less than a fifth of a percent would require 500 treatments at standard dose! That is why a multiple of plasma amounts paradoxically are less good the better the efficiency of the effect aimed at in the plasma.
I trust AS (Alan lol) when he uses those words about the actual levels released, and hope his accuracy of semantics is better than his timeline promises!
OAMOT, I have been trawling my browser history, but can't find the Avacta page I got the 30% fig from, and can't find it navigating on their site.
Do you have a link to 18x? If you are right, I will sell the house and put it all into AVCT!
Sorcerer, I would add an important third, how much dox released in the TME relative to amount in the dose of ava6k administered.
Yes, the 17th Jan RNS told us it worked, fantastic. How well? "typical drug-related cardiotoxicity of dox not observed" - big tick. "therapeutic levels which are much higher than. . .bloodstream" - tick, but with a question?
So number one, yes, positive, and we saw a good rise in SP. Number two? well Avacta is not a secret that only PIs like us on this board know about. The IIs and people in the field will be well aware, and have positions, or waiting for further details and or progress. Yes Joe Public down the pub probably won't have heard of Avacta, so we could get more SP rise the more PIs get to hear of Avacta.
I think number three is as, if not more important than number 1. I am over exposed, and was going to be one of those idiots taking some profit today if no material news, i.e. details were to be released. Being an PI, the price moved before I could get in though.
So, my thoughts on what detail I was hoping for, and might still get (we will find out tomorrow) In laymans terms, at a normal 60-75mg/m2 of dox in a shot of 6k, what percent was cleaved at the tumor site. We know it is low in the blood, so that box can be considered ticked, only how well it cleaves is the remaining question.
There was a link on this bb to Avactas study in mice or rats, can't remember, but the dox percent seemed about 30% in the best cases, and much lower in others. They were able to get similar levels in artificially fap enhanced environments similar to straight dox, but that's not real world.
So, a measure of how much in the TME is the key, "therapeutic" or "much higher than blood" are very encouraging, (hence "it works"tm) but a tease.
A thought experiment, down side, assume say one percent of given dox total found in blood, much higher in TME, 3%?, 10%?, 30%? Is 3% therapeutic, or "significant"? I guess so, better than 1%, but would need 33 treatments to equal one dox only treatment, and a whopping 300 plus to get to or exceed the MTD of straight dox! Hence DE.
Thought experiment part 2. DE is at 2x normal dose, further DE finds can get to 3, 4 or 5 times without cardio side effects. Treatment can be quicker intervals too, say 3 to 4 times normal dose, every week instead of 3 weekly, now we are talking. Does anyone know how often the P1a trials were administering?
So, best case scenario, much more 6k into patient, minimal to no side effects, would need roughly 10% of the dox released at straight 60-75mg for same amount to the TME, same time frame, but triple doses. Of course the maximum lifetime could be exceeded, but how many treatments are practical?
For me, getting an answer of 10% or more, winner winner chicken dinner, low single percent? hmm, maybe more work needed. just my laymans view
P.S. While I have been composing my thoughts, the SP has come back, but I have half talked myself out of par
I like many was hoping for a RNS today, but tomorrow would be a more logical date.
Either SD will be revealing market sensitive data, or just basically presenting info we already know to the attendees.
If new details, I would expect an RNS, if just a presentation for II's, then not.
I am tempted to give my thoughts on where we are from the Jan 17th RNS, but would end up being called a FUDer, as this BB has become quite tribal. Roll on SD!
Luke, "tolerated and is activating" - I'll be doing summersaults!
As has been discussed here many times, we can be pretty sure it is tolerated well, as cohorts have got to 4.
As I read it, the RNS does not have to mention activation, or successful cleaving, Dox found in the TME etc, but hopefully it will.
At this stage, I couldn't care less about details of efficiency, any news that they have found dox in the TME, will send the SP well over £3 I would imagine, maybe not in one day though!
I am looking forward to the RNS next week, but don't care if it's Jan 31st, as long as there is a hint dox is being delivered.
We know from the logic endlessly discussed on this board, they are happy with the dose tolerability.
I would like a bit more than the usual AS bit of leg "very happy with trial data, details on science day"!
earlstone, entirely possible.
This is my theory though.
Fiona said in an interview about ava6k "delivers a drug". The official line is of course AIMS to deliver etc. Cue much excitement on twitter Sunday, and SP starts rising this morning.
It then transpires she will be talking at the event on the 5th Nov, without looking it up, I can't remember if before or after the "delivers a drug" statement, but this combines to turbo the SP.
Avacta notice, and quickly RNS "no new news on the 5th".
The funny thing is, this reverses some of the rise, but they didn't (couldn't?) disown the "delivers a drug" statement.
So this coming weekend is basically a promotion exercise, fine, as others have noted, would they bother if it was a fail, which they will know by now. .
I've been anxious in the past, as I've topped up so much I'm well overweight AVCT, but I'm more relaxed as time goes on. Not long to wait anyway